Cytokine signature in convalescent SARS-CoV-2 patients with inflammatory bowel disease receiving vedolizumab

Cytokine signature in convalescent SARS-CoV-2 patients with inflammatory bowel disease receiving vedolizumab

Abstract While differential antibody responses SARS-CoV-2 in patients with inflammatory bowel disease (IBD) receiving infliximab and vedolizumab are well-characterized, the immune pathways underlying these differences remain unknown. Prior to COVID-19 vaccine development, we screened 235 patients wi...

Full description

Bibliographic Details
Main Authors: Simone Dallari, Vicky Martinez Pazos, Juan Munoz Eusse, Judith Wellens, Craig Thompson, Jean-Frederic Colombel, Jack Satsangi, Ken Cadwell, Serre-Yu Wong, ICARUS-IBD Working Group
Format: Article
Language:English
Published: Nature Portfolio 2024-01-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-50035-1

Internet

https://doi.org/10.1038/s41598-023-50035-1

Similar Items